Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 03 Jul 2025
Bayer's Adempas gets insurance coverage in Korea 11 years after approval
21 May 2025 - The pulmonary arterial hypertension medicine Adempas (riociguat) will be covered by national health insurance starting next ...
Posted by Michael Wonder on 03 Jul 2025
Apotex receives Health Canada approval for Aflivu, a biosimilar to Eylea, available in pre-filled syringe and vial formats
2 July 2025 - Apotex today announced that Health Canada has approved Aflivu (aflibercept), a biosimilar to Eylea, indicated for ...
Posted by Michael Wonder on 03 Jul 2025
FDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
2 July 2025 - Today, the FDA granted accelerated approval to sunvozertinib (Zegfrovy, Dizal) for adult patients with locally advanced ...
Posted by Michael Wonder on 03 Jul 2025
Top level push for taxpayer funding of weight loss drugs gathers pace
3 July 2025 - Pharma giants are sweating on the results of a federal government request for guidance on adding weight ...
Posted by Michael Wonder on 03 Jul 2025
Big pharma calls out Australia’s ‘freeloading’ on US medicine
3 July 2025 - American pharmaceutical manufacturers have ramped up pressure on Donald Trump to take action against Australia over its ...
Posted by Michael Wonder on 03 Jul 2025
FDA grants priority review for Winrevair (sotatercept-csrk) to update label based on results from ZENITH trial
2 July 2025 - Merck today announced that the US FDA has accepted and granted priority review for a new supplemental ...
Posted by Michael Wonder on 03 Jul 2025
FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma
2 July 2025 - Today the FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals), a bispecific B-cell maturation antigen ...
Posted by Michael Wonder on 02 Jul 2025
Calls for 'missing piece' menopause drug to be added to the PBS
2 July 2025 - A key treatment which could help around one million middle-aged Australian women remains unaffordable to many ...
Posted by Michael Wonder on 02 Jul 2025
Life-saving breast cancer drug now cheaper thanks to expansion of the PBS
1 July 2025 - A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...
Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...
Posted by Michael Wonder on 01 Jul 2025
New Zealand Pharmaceutical Schedule - 1 July 2025
1 July 2025 - The July 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Jul 2025
NICE welcomes the inclusion of measures for equal treatment of medicines and health technologies
1 July 2025 - The new approach will ensure that high impact devices, diagnostics and digital tools recommended by NICE, that ...
Posted by Michael Wonder on 01 Jul 2025
Schedule of Pharmaceutical Benefits - 1 July 2025
1 July 2025 - The July 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Jul 2025
Unicycive Therapeutics announces receipt of complete response letter for oxylanthanum carbonate for the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis
30 June 2025 - No other concerns stated, including pre-clinical, clinical, or safety data. ...
Posted by Michael Wonder on 01 Jul 2025
Takeda announces US FDA approval of Gammagard Liquid ERC, the only ready to use liquid immunoglobulin therapy with low immunoglobulin A content
30 June 2025 - US commercialisation of Gammagard Liquid ERC projected to begin in 2026. ...